From the Research
Anti-Smith (Anti-SM) and Anti-Jo-1 antibodies do not play a significant role in the treatment or diagnosis of psoriasis, as the current evidence does not support their involvement in the disease process. The most recent and highest quality study, a network meta-analysis published in 2022 1, compared the efficacy and safety of various treatments for moderate-to-severe psoriasis, but did not mention Anti-SM or Anti-Jo-1 antibodies.
Key Points:
- Psoriasis is a chronic inflammatory disease with a strong genetic component, and its treatment depends on the severity of the disease.
- Biologic medications, such as tumor necrosis factor (TNF) inhibitors, interleukin-12 (IL-12) inhibitors, interleukin-23 (IL-23) inhibitors, and interleukin-17 (IL-17) inhibitors, are effective treatments for moderate to severe psoriasis.
- The most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis are biologics such as infliximab, bimekizumab, ixekizumab, and risankizumab, according to the 2022 network meta-analysis 1.
- Switching biologic agents can significantly improve outcomes for patients who fail to respond well to their first biologic agent, as discussed in a 2018 review 2.
Treatment Options:
- Topical medications, such as corticosteroids and vitamin D analogs, are commonly used for mild to moderate psoriasis.
- Phototherapy and non-biologic systemic medications, such as methotrexate and ciclosporin, are also used for moderate to severe psoriasis.
- Biologic medications, such as TNF inhibitors, IL-12 inhibitors, IL-23 inhibitors, and IL-17 inhibitors, are effective treatments for moderate to severe psoriasis, as shown in the 2022 network meta-analysis 1.
Monitoring and Precautions:
- Patients should undergo screening for tuberculosis and other infections before starting biologic medications.
- Regular monitoring during treatment is essential, and biologic medications should be used with caution in patients with certain conditions, such as heart failure, multiple sclerosis, or a history of cancer.